Department of Molecular and Cellular Biology,
Lester and Sue Smith Breast Center,
Dan L. Duncan Cancer Center
Lacey E. Dobrolecki has not added Biography.
If you are Lacey E. Dobrolecki and would like to personalize this page please email our Author Liaison for assistance.
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.
PloS one , 2012 | Pubmed ID: 22879872
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Cancer research Aug, 2013 | Pubmed ID: 23737486
Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy.
Journal of biomolecular screening Jul, 2014 | Pubmed ID: 24525869
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
Oncogene Mar, 2015 | Pubmed ID: 24681959
A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.
Molecular pharmacology Feb, 2015 | Pubmed ID: 25480843
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Breast cancer research : BCR , 2015 | Pubmed ID: 25572662
Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Breast cancer research : BCR Jan, 2016 | Pubmed ID: 26757880
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.
Nature cell biology Jun, 2016 | Pubmed ID: 27183469
Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Cancer metastasis reviews 12, 2016 | Pubmed ID: 28025748
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.
Nature 04, 2017 | Pubmed ID: 28371798
Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.
Acta biomaterialia 08, 2017 | Pubmed ID: 28465075
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.
The Journal of clinical investigation 04, 2018 | Pubmed ID: 29480818
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nature medicine 05, 2018 | Pubmed ID: 29578538
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.
Nature communications 09, 2018 | Pubmed ID: 30232459
C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.
Oncogene 05, 2019 | Pubmed ID: 30262865
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
BMC cancer Mar, 2019 | Pubmed ID: 30871481
Chromosome 12p Amplification in Triple-Negative/Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
Cancer research 08, 2019 | Pubmed ID: 31213465
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
Molecular cancer research : MCR 10, 2019 | Pubmed ID: 31320385
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.
Journal of clinical medicine 10, 2019 | Pubmed ID: 31652963